BACKGROUND: Small-bowel adenocarcinoma (SBA) is a rare tumor that has a poor response to chemotherapy and a poor prognosis. Treatment strategies for SBA have not been clearly established. METHODS: All patients with SBA treated using a combination of cisplatin and irinotecan (IP) as first-line chemotherapy at the National Cancer Center Hospital in Japan between January 1999 and February 2007 were studied retrospectively. RESULTS: Eight patients received IP as first-line chemotherapy. The median follow-up was 9.5 months (range, 4.2-37.5 months). The median number of cycles of IP was three (range, 1-5). The overall response rate (complete or partial response) was 12.5% (complete response, n = 0; partial response, n = 1). The disease control rate (complete or partial response or stable disease) was 75%. The median time to treatment failure was 4.5 months (95% confidence interval, 0.9-5.8 months), and overall survival was 17.3 months (range, 1.9-21.3 months). The most common adverse events were neutropenia and anorexia. CONCLUSION: IP combination chemotherapy may be an acceptable option for patients with SBA. Further studies are warranted to determine the optimal chemotherapeutic regimen for SBA.
BACKGROUND:Small-bowel adenocarcinoma (SBA) is a rare tumor that has a poor response to chemotherapy and a poor prognosis. Treatment strategies for SBA have not been clearly established. METHODS: All patients with SBA treated using a combination of cisplatin and irinotecan (IP) as first-line chemotherapy at the National Cancer Center Hospital in Japan between January 1999 and February 2007 were studied retrospectively. RESULTS: Eight patients received IP as first-line chemotherapy. The median follow-up was 9.5 months (range, 4.2-37.5 months). The median number of cycles of IP was three (range, 1-5). The overall response rate (complete or partial response) was 12.5% (complete response, n = 0; partial response, n = 1). The disease control rate (complete or partial response or stable disease) was 75%. The median time to treatment failure was 4.5 months (95% confidence interval, 0.9-5.8 months), and overall survival was 17.3 months (range, 1.9-21.3 months). The most common adverse events were neutropenia and anorexia. CONCLUSION:IP combination chemotherapy may be an acceptable option for patients with SBA. Further studies are warranted to determine the optimal chemotherapeutic regimen for SBA.
Authors: Paula N Fishman; Gregory R Pond; Malcolm J Moore; Amit Oza; Ronald L Burkes; Lillian L Siu; Ronald Feld; Steven Gallinger; Paul Greig; Jennifer J Knox Journal: Am J Clin Oncol Date: 2006-06 Impact factor: 2.339
Authors: K Shirao; Y Shimada; H Kondo; D Saito; T Yamao; H Ono; T Yokoyama; H Fukuda; M Oka; Y Watanabe; A Ohtsu; N Boku; T Fujii; Y Oda; K Muro; S Yoshida Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544